全文获取类型
收费全文 | 302篇 |
免费 | 15篇 |
专业分类
儿科学 | 13篇 |
基础医学 | 32篇 |
口腔科学 | 9篇 |
临床医学 | 12篇 |
内科学 | 54篇 |
皮肤病学 | 70篇 |
神经病学 | 30篇 |
特种医学 | 9篇 |
外科学 | 40篇 |
综合类 | 2篇 |
预防医学 | 13篇 |
眼科学 | 1篇 |
药学 | 24篇 |
肿瘤学 | 8篇 |
出版年
2023年 | 2篇 |
2022年 | 3篇 |
2021年 | 11篇 |
2020年 | 3篇 |
2019年 | 12篇 |
2018年 | 5篇 |
2017年 | 4篇 |
2016年 | 2篇 |
2015年 | 5篇 |
2014年 | 2篇 |
2013年 | 7篇 |
2012年 | 12篇 |
2011年 | 18篇 |
2010年 | 12篇 |
2009年 | 16篇 |
2008年 | 17篇 |
2007年 | 23篇 |
2006年 | 11篇 |
2005年 | 12篇 |
2004年 | 13篇 |
2003年 | 13篇 |
2002年 | 11篇 |
2001年 | 13篇 |
2000年 | 10篇 |
1999年 | 8篇 |
1998年 | 2篇 |
1997年 | 2篇 |
1996年 | 4篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 2篇 |
1992年 | 13篇 |
1991年 | 8篇 |
1990年 | 6篇 |
1989年 | 2篇 |
1988年 | 3篇 |
1986年 | 2篇 |
1985年 | 5篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1981年 | 2篇 |
1980年 | 1篇 |
1979年 | 4篇 |
1978年 | 1篇 |
1976年 | 1篇 |
1974年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
1969年 | 1篇 |
排序方式: 共有317条查询结果,搜索用时 0 毫秒
61.
Stefania Seidenari Anna Di Nardo Alberto Giannetti 《Journal of the European Academy of Dermatology and Venereology》1994,3(4):468-474
Background The inhibitory activity of methylprednisolone aceponate (MPA) on experimentally induced allergic reactions was assessed by an echographic method employing a B-scanner and a dedicated software, and compared to the effects of corticosteroids of known potency. Material and methods Experimental lesions, which were induced by patch testing 12 sensitized subjects with 5% nickel sulfate (pet.), were treated with two medications of different steroids (clobetasol propionate, fluocinolone acetonide, clobetasone butyrate, and methylprednisolone aceponate), performed 16 and 40 h after the application of the nickel patch tests. Clinical and echographic evaluations were carried out at the beginning of the experiment, and 64 hours after the induction of the reactions, Values of skin thickness and of extension of hypo-reflecting dermal areas were determined by image processing on echographic recordings. Results Rank order of the potency of the tested corticostcroids, as evaluated by echography, was the same as the one obtained by visual scoring. MPA proved to be less effective than clobetasol propionate, more effective than clobetasone butyrate. and equally as effective as fluocinolone acetonide. Conclusion This experiment indicated MPA can be considered a potent steroid. 相似文献
62.
Granulocyte macrophage colony-stimulating factor is overproduced by keratinocytes in atopic dermatitis. Implications for sustained dendritic cell activation in the skin. 总被引:5,自引:2,他引:3
下载免费PDF全文
![点击此处可从《The Journal of clinical investigation》网站下载免费的PDF全文](/ch/ext_images/free.gif)
S Pastore E Fanales-Belasio C Albanesi L M Chinni A Giannetti G Girolomoni 《The Journal of clinical investigation》1997,99(12):3009-3017
Lesional skin of atopic dermatitis (AD) harbors high numbers of dendritic cells with enhanced stimulatory capacity for T lymphocytes. In this study, lesional AD skin was shown to stain heavily in both epidermal and dermal compartments for GM-CSF, a cytokine crucial to dendritic cell functions. Keratinocyte cultures established from uninvolved skin of AD patients exhibited markedly increased spontaneous and PMA-stimulated release of GM-CSF compared with keratinocytes from nonatopic controls. Correspondingly, keratinocytes from AD patients showed higher constitutive as well as PMA-induced GM-CSF gene expression. Larger amounts of GM-CSF were produced by AD keratinocytes, also in response to IL-1alpha, but not after stimulation with LPS, lipoteichoic acid, or staphylococcal enterotoxin B. Hydrocortisone reduced GM-CSF gene expression and protein release in both atopic and control keratinocytes. Supernatants from atopic keratinocytes were able to strongly stimulate PBMC proliferation in a GM-CSF-dependent manner. Moreover, conditioned medium from PMA-treated AD keratinocytes, together with exogenous IL-4, could support phenotypical and functional maturation of peripheral blood precursors into dendritic cells. Enhanced production of GM-CSF by keratinocytes may contribute relevantly to the establishment and chronicity of AD lesions, in particular to the increased number, sustained activation, and enhanced antigen-presenting functions of dendritic cells. 相似文献
63.
The adhesion and growth of cells on silicon dioxide substrata are analysed. The adhesion of human red blood cells to silicon dioxide layers of different depth and doping compares well with that to glass. Rat pheochromocytoma cells also grow on the same substrata. The adhesion of these two biological systems is characterized at the microscopic level by using the quite new technique of scanning reflection acoustic microscopy. Possible future developments towards the functional coupling of living cells to microelectronic integrated circuits are briefly discussed. 相似文献
64.
Wolfram Sterry Georg Stingl Richard G.B. Langley Hugh Zacharie Morad Lahfa Alberto Giannetti Carlos Ferrndiz Rodney Sinclair Jean‐Hilaire Saurat 《Journal der Deutschen Dermatologischen Gesellschaft》2006,4(11):947-956
Background: The 12‐week, double‐blind, placebo‐controlled, first‐treatment (FT) CLEAR trial period demonstrated the efficacy/safety of efalizumab in moderate‐to‐severe plaque psoriasis, including refractory or contraindicated patients unsuitable for other systemic treatments. This study assessed the efficacy/safety of open‐label extended treatment (up to 24 weeks' continuous treatment) in patients not achieving ≥75% improvement in Psoriasis Area and Severity Index (PASI‐75) at week 12 of the FT period. Time to relapse after treatment cessation, and efficacy/safety of 12 weeks' open‐label re‐treatment in patients achieving PASI‐75 at week 12 FT were also assessed. Patients and methods: Patients with PASI‐75 at week 12 FT were observed without treatment until relapse, then re‐treated with open‐label efalizumab (1.0 mg/kg/week for 12 weeks). Others received open‐label extended treatment without intervening observation. Results: Among efalizumab‐treated patients (n = 308) who had < 75% PASI improvement at week 12 FT, extended treatment led to PASI‐75 in 26.6%. Among patients with between ≥ 50 and < 75% PASI improvement at week 12 FT (n = 118), 47.5% improved to PASI‐75 with extended treatment. Forpatients achieving PASI‐75 at week 12 FT (n = 164), median time to relapse was 58 days. Re‐treatment after relapse led to mean PASI improvement of 62.3% from study baseline (n = 145). Safety results were consistent with pre‐vious studies, with no new safety concerns. Conclusions: These results demonstrate additional benefit of continuing efali‐zumab. Re‐treatment re‐established disease control in patients with PASI‐75 who relapsed following treatment cessation. The safety profile remained consistent with that seen at 12 weeks. 相似文献
65.
66.
Rahul Khairnar Khalid M. Kamal Vincent Giannetti Nilanjana Dwibedi Jamie McConaha 《Research in social & administrative pharmacy》2019,15(3):279-286
Background
Diabetes self-management (DSM) is a key element in the overall management of type-2 diabetes (T2DM). Identifying barriers and facilitators to DSM and addressing them is a critical step in achieving improved health outcomes in this population.Objective
To assess patient reported barriers and facilitators to self-management of T2DM in a primary care setting.Methods
This cross sectional study combined patient survey data with electronic medical record (EMR) data. Patients (age≥18 years) with a recorded diagnosis of T2DM (ICD-9 code: 250. xx) and having ≥2 physician visits were identified from a physician group's EMR database. Patients were grouped based on their A1C levels: <7, 7–9, and >9. Information on demographics, knowledge of diabetes, attitudes, health beliefs, and level of self-management was collected through survey administration. Survey responses were linked to the EMR data, and additional patient information was extracted.Results
A total of 2100 surveys were administered (700 in each A1C category) of which 210 responses were received (10% response rate). Mean age was 63.7 years ( ±11.79), 108 (51.4%) were males, and 197 (93.8%) were Caucasian. Age (X2?=?15.73, p?<?0.01), insurance status (X2?=?12.03, p?<?0.05), referral to an endocrinologist (X2?=?6.17, p?<?0.05), level of self-management (X2?=?12.01, p?<?0.05) and willingness to use insulin (X2?=?9.8, p?<?0.01) were associated with glycemic variability. Level of self-management (X2?=?33.04, p?<?0.01) and referral to an endocrinologist (X2?=?11.11, p?<?0.01) were associated with readiness to change DSM behavior. Better self-management, older age, lower willingness to use insulin, and ‘less than graduate level’ education were significant predictors of glycemic stability.Conclusions
Self-management behavior of patients with T2DM is strongly associated with glycemic stability. Interventions directed towards improving self-management in this population may result in improved clinical outcomes. 相似文献67.
68.
F. Farnetani M. Manfredini S. Longhitano J. Chester K. Shaniko E. Cinotti L. Mazzoni M. Venturini A. Manganoni C. Longo L. Reggiani‐Bonetti L. Giannetti P. Rubegni P. Calzavara‐Pinton I. Stanganelli J.L. Perrot G. Pellacani 《Journal of the European Academy of Dermatology and Venereology》2019,33(4):676-685
69.